Traders should monitor upcoming clinical trial initiations in 2026 as key catalysts; any interim data readouts or regulatory designations (e.g., Breakthrough Therapy) could drive further upside. The lack of current treatment options increases commercial potential if efficacy is confirmed.
TRVI drugs
TRVI drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 9 $11.70entry
- T+1 · 8mo ago +0.51%α +0.70% · $11.76
- T+5 · 8mo ago −4.62%α −3.26% · $11.16
- T+20 · 7mo ago +11.97%α +14.77% · $13.10
- T+60 · 6mo ago +15.38%α +3.40% · $13.50
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Trevi Therapeutics announced positive feedback from its End-of-Phase 2 meeting with the FDA, confirming the development path for Haduvio™ (nalbuphine ER) in IPF-related chronic cough. The company plans to initiate two parallel Phase 3 trials in 2026, marking a significant step toward a potential NDA submission for a condition with no approved therapies.
Key Facts
- FDA alignment achieved on Phase 3 trial design and remaining development program for nalbuphine ER in IPF-related chronic cough
- Two pivotal Phase 3 trials planned: one with ~300 patients (52-week dosing, primary endpoint at 24 weeks), another with ~130 patients (12-week dosing)
- First Phase 3 trial on track to initiate in Q2 2026, second in H2 2026
- Primary endpoint for both trials: relative change in 24-hour cough frequency vs. placebo using objective cough monitoring
- No FDA-approved therapies currently exist for IPF-related chronic cough, representing a significant unmet medical need
Financial Impact
Potential path to approval for a first-in-class therapy in a high-unmet-need indication with ~100,000 U.S. patients affected (two-thirds of 150,000 IPF patients)
Risk Factors
- Phase 3 trial results may not replicate prior positive data
- Regulatory delays or protocol disagreements with FDA could push back timelines
- High cash burn risk given upcoming pivotal trials; potential for near-term dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251724 |
Track record
12 reports on TRVI
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $14.91 Now $13.29 −10.87% settles Dec 9
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $13.52 Now $13.29 −1.70% settles Nov 25
- Jun 11, 202622w ago Institutional Cluster Mixed 5/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $14.80 to $13.24 Now $13.29 −10.20% ▼ −10.54% −13.71% vs SPY
- Apr 20, 202630w ago Press Release Neutral 5/10 Entry $14.62 to $13.43 Now $13.29 −9.10% ▼ −8.14% −13.05% vs SPY
- Apr 17, 202630w ago 424B5 Bearish 7/10 Entry $15.40 to $13.43 Now $13.29 +13.70% ▲ +12.79% +16.99% vs SPY
- Apr 17, 202630w ago 8-K Bearish 7/10 Entry $15.23 to $15.08 Now $13.29 +12.74% ▲ +0.98% +6.36% vs SPY
- Apr 16, 202630w ago Press Release Neutral 6/10 Entry $15.23 to $15.08 Now $13.29 −12.74% ▼ −0.98% −6.36% vs SPY
- Mar 17, 202634w ago Press Release Mixed 6/10 Entry $10.69 to $14.54 Now $13.29 +24.32% ▲ +36.02% +29.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers